+

WO2009038659A3 - Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy - Google Patents

Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy Download PDF

Info

Publication number
WO2009038659A3
WO2009038659A3 PCT/US2008/010608 US2008010608W WO2009038659A3 WO 2009038659 A3 WO2009038659 A3 WO 2009038659A3 US 2008010608 W US2008010608 W US 2008010608W WO 2009038659 A3 WO2009038659 A3 WO 2009038659A3
Authority
WO
WIPO (PCT)
Prior art keywords
photosensitizers
nanoparticles
imaging agents
covalently linked
photosensitizer
Prior art date
Application number
PCT/US2008/010608
Other languages
French (fr)
Other versions
WO2009038659A2 (en
Inventor
Ravindra Pandey
Lalit Goswami
Allan Oseroff
Janet Morgan
Paras Prasad
Earl Bergey
Tymish Ohulchanskyy
Indrajit Roy
Original Assignee
Health Research, Inc.
The Research Foundation Of State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research, Inc., The Research Foundation Of State University Of New York filed Critical Health Research, Inc.
Publication of WO2009038659A2 publication Critical patent/WO2009038659A2/en
Publication of WO2009038659A3 publication Critical patent/WO2009038659A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Nanoparticles containing covalently linked photosensitizer molecules that overcome the drawback of premature release and thus enhance the outcome of PDT. [Silica-based nanoparticles are provided containing at least one covalently linked photosensitizer. The photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines, naphthanocyanines with and without fused ring systems and derivatives of all the above. The nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents. The imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency. Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers.
PCT/US2008/010608 2007-09-14 2008-09-11 Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy WO2009038659A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99380707P 2007-09-14 2007-09-14
US60/993,807 2007-09-14

Publications (2)

Publication Number Publication Date
WO2009038659A2 WO2009038659A2 (en) 2009-03-26
WO2009038659A3 true WO2009038659A3 (en) 2009-09-03

Family

ID=40468678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010608 WO2009038659A2 (en) 2007-09-14 2008-09-11 Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy

Country Status (1)

Country Link
WO (1) WO2009038659A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110718966B (en) * 2019-10-25 2020-12-25 云南电网有限责任公司信息中心 Data acquisition and management method for power equipment

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2464958A (en) * 2008-10-31 2010-05-05 Univ Muenster Wilhelms A method for the manufacture of a photosensitising nano-material
JP5662431B2 (en) * 2009-06-12 2015-01-28 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム Targeted nanophotomedicine for photodynamic therapy of cancer
FR2956109B1 (en) * 2010-02-11 2012-04-20 Commissariat Energie Atomique PROCESS FOR THE STOBER PREPARATION OF SILICA PARTICLES CONTAINING A PHTHALOCYANINE DERIVATIVE, THE SAID PARTICLES AND USES THEREOF
US8609837B2 (en) 2010-07-06 2013-12-17 Health Research, Inc. Metallation enhancements in tumor-imaging and PDT therapy
EP2484388A1 (en) * 2011-02-05 2012-08-08 MaRVis Technologies GmbH Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it
JP6145407B2 (en) * 2011-11-18 2017-06-14 株式会社Adeka Novel compound and carrier carrying the novel compound
EP2692365A1 (en) 2012-08-03 2014-02-05 MaRVis Medical GmbH Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
US9119875B2 (en) 2013-03-14 2015-09-01 International Business Machines Corporation Matrix incorporated fluorescent porous and non-porous silica particles for medical imaging
PT107125B (en) * 2013-08-23 2019-02-13 Inst Superior Tecnico SUPERPARAMAGNETIC MULTIFUNCTIONAL NANOSYSTEM AS A CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGE AND ITS PRODUCTION METHOD
WO2016094991A1 (en) * 2014-12-16 2016-06-23 Universidade Estadual De Campinas - Unicamp Method for producing pegylated silica nanoparticles as carriers of hydrophobic pharmaceutical drugs, thus obtained nanoparticles and uses thereof
CN113546042A (en) * 2021-07-22 2021-10-26 中国药科大学 An acid-responsive nanomicelle based on the Cherenkov effect and its preparation method and application
CN115364211B (en) * 2022-08-02 2023-12-22 北京大学 Ultra-small phthalocyanine conjugated mesoporous silica nanoparticle and application thereof as sound sensitizer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20030157021A1 (en) * 1995-02-02 2003-08-21 Jo Klaveness Light imaging contrast agents
US20040180096A1 (en) * 2003-01-24 2004-09-16 Paras Prasad Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20030157021A1 (en) * 1995-02-02 2003-08-21 Jo Klaveness Light imaging contrast agents
US20040180096A1 (en) * 2003-01-24 2004-09-16 Paras Prasad Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110718966B (en) * 2019-10-25 2020-12-25 云南电网有限责任公司信息中心 Data acquisition and management method for power equipment

Also Published As

Publication number Publication date
WO2009038659A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2009038659A3 (en) Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy
Chen et al. Gadolinium‐encapsulated graphene carbon nanotheranostics for imaging‐guided photodynamic therapy
US20220296714A1 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
Li et al. Photosensitized singlet oxygen generation and detection: Recent advances and future perspectives in cancer photodynamic therapy
Guan et al. Photodynamic therapy based on nanoscale metal–organic frameworks: from material design to cancer nanotherapeutics
Li et al. Sequential protein-responsive nanophotosensitizer complex for enhancing tumor-specific therapy
Ding et al. Zinc (II) metalated porphyrins as photothermogenic photosensitizers for cancer photodynamic/photothermal synergistic therapy
Wang et al. Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics
Abrahamse et al. New photosensitizers for photodynamic therapy
Ishii Functional singlet oxygen generators based on phthalocyanines
Ethirajan et al. The role of porphyrin chemistry in tumor imaging and photodynamic therapy
EP2437653B1 (en) Paa nanoparticles for enhancement of tumor imaging
Song et al. Metal–organic frameworks for photodynamic therapy: emerging synergistic cancer therapy
Bloyet et al. Photosensitizer encryption with aggregation enhanced singlet oxygen production
Yao et al. Boron‐Fluorine Photosensitizers for Photodynamic Therapy
Arguinzoniz et al. Light harvesting and photoemission by nanoparticles for photodynamic therapy
Boscencu et al. Porphyrin Macrocycles: General Properties and Theranostic Potential
Liu et al. Porphyrin‐Based Nanoparticles: A Promising Phototherapy Platform
Xie et al. Recent Advances in Tetrakis (4‐Carboxyphenyl) Porphyrin‐Based Nanocomposites for Tumor Therapy
Fabris et al. Tumour-localizing and-photosensitising properties of meso-tetra (4-nido-carboranylphenyl) porphyrin (H2TCP)
Dumoulin Design and conception of photosensitisers
Bechet et al. Innovations of photodynamic therapy for brain tumors: Potential of multifunctional nanoparticles
US8906343B2 (en) PAA nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded
Ohishi et al. Water-Soluble Rotaxane-Type Porphyrin Dyes as a Highly Membrane-Permeable and Durable Photosensitizer Suitable for Photodynamic Therapy
Sève et al. Long-distance energy transfer photosensitizers arising in hybrid nanoparticles leading to fluorescence emission and singlet oxygen luminescence quenching

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832507

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08832507

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载